Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 26

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 26
---
 Mr. Gonzalez’s responsibilities

34 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

as Executive Chairman, the value of his insight during this critical period of transition, and the importance of facilitating a smooth leadership change. The Committee also engaged its independent compensation consultant, Semler Brossy, to provide their insight into the competitive market for Executive Chair roles following service as CEO. Mr. Gonzalez’s pay package is consistent with the external competitive market, which the Compensation Committee believes is appropriate based on his leadership in the role and performance track record as CEO. BUSINESS PERFORMANCE HIGHLIGHTS Advanced our strategy through outstanding operational execution and investments in innovation during 2024

| ​                                         | ​ | ​ | ​                                  | ​ | ​ | ​                                      |
| Total Net Revenues                        |   |   | Growth Platform Net Revenues       |   |   | Operating Cash Flow                    |
| $56.3BN                                   | ​ | ​ | $47.3BN                            | ​ | ​ | $18.8BN                                |
| 4.6% operational growth compared to 2023* | ​ | ​ | +18.6% compared to 2023**          | ​ | ​ | in 2024                                |
| ​                                         | ​ | ​ | ​                                  | ​ | ​ | ​                                      |
| ​                                         | ​ | ​ | ​                                  | ​ | ​ | ​                                      |
| Blockbuster Products                      | ​ | ​ | Adjusted R&D Investment            | ​ | ​ | Development Pipeline                   |
| 12                                        | ​ | ​ | $10.8BN                            | ​ | ​ | ~90                                    |
| assets with 2024 net revenues > $1.0BN    | ​ | ​ | increased $3.0BN compared to 2023* | ​ | ​ | active clinical and device programs*** |

The measures set forth in this table were calculated as of 12/31/2024. * Reflects a non-GAAP measure and is adjusted for certain items, which are reconciled in Appendix B. Operational growth is presented at constant currency rates that reflect comparative local currency net revenues at the prior year’s foreign exchange rates. **Growth Platform reflects total net revenues less Humira net revenues. ***Compounds, devices or indications in development individually or under collaboration or license agreements. Strong operational execution

| ● | Total net revenues of $56.3 billion, driven by strong performance from our Growth Platform